Apollomics
APLM
Apollomics (APLM) news
Recent news
ApolloMics reports $10M placement transaction
AInvest Wire · Aug 11, 2026ApolloMics regains full compliance with Nasdaq listing requirements
AInvest Wire · Jul 13, 2026ApolloMics: termination due to Launxp's failure to cure material breach of its obligations under agreement
AInvest Wire · Jun 24, 2026ApolloMics Inc: Effective June 11, co formally terminated collaboration & license agreement with Launxp International
AInvest Wire · Jun 24, 2026Apollomics - regains rights to Vebreltinib (APL-101) in Asia
Apollomics Inc. (Nasdaq: APLM) has entered into a licensing agreement with LaunXP Biomedical, granting the latter exclusive rights to develop and commercialize vebreltinib (APL-101) in combination with an EGFR inhibitor in Asia, excluding mainland China, Hong Kong, and Macau. Under the terms of the…
AInvest Wire · Jun 24, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.